1. Scrip
  2. >>R&D

Filings Soon As Biogen Snaps Up Ionis' Antisense Treatment

 
• By Alexandra Shimmings

Promising top-line Phase III data have prompted Biogen to exercise an option to develop and commercialize Ionis's novel antisense treatment nusinersen for infantile-onset spinal muscular atrophy; filings are due shortly.

DNA
• Source: Shutterstock

Shares in Carlsbad, CA-based Ionis Pharmaceuticals Inc. (formerly ISIS Pharmaceuticals) shot up by more than 30% to close at $38.01 on Aug. 1 when it announced the initial data from its ENDEAR study of the antisense candidate nusinersen plus a $75m license fee payment from Biogen Inc.,which will now assume responsibility for the drug's development. Biogen's shares also received a 4% boost.

A pre-specified interim analysis has shown that babies with infantile-onset (consistent with Type 1) spinal muscular atrophy (SMA) receiving nusinersen...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Scrip

China Signals Restarting IPOs For Unprofitable Biotechs

 
• By Dexter Jie Yan

The China Securities Regulatory Commission has proposed a new “growth tier” for the STAR Market of the Shanghai Stock Exchange, to reinstate the market’s listing standards for unprofitable firms.

BIO Notebook: Woodcock Calls For Doing The Right Thing, Dealmaking Remains Constrained

 
• By Mandy Jackson, Joseph Haas, and Sarah Karlin-Smith

Highlights from Day Four of the BIO International Convention include Woodcock offering practical advice on rare disease trials, the sorry state of dealmaking mid-year, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.

Syncona Looks To Go Private As Market Decline Deepens

 
• By Andrew McConaghie

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.